ReviewFrontiers in immunology2026
Development and clinical application of recombinant polyclonal antibodies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs) have transformed the treatment of cancer and immune disorders, but their single-target nature limits efficacy against heterogeneous tumors and mutating pathogens. Recombinant polyclonal antibodies (RPABs)-defined as mixtures of typically 2-25 defined mAbs produced as a single drug substance from one mixed master cell bank-were proposed to combine the epitope breadth of polyclonal antibodies with the manufacturing consistency of mAbs. This review critically analyzes the four RPABs candidates that have entered clinical trials to date (Sym001, Sym004, Sym013, and Sym015), all developed by Symphogen using its proprietary Sympress™ platform. We identify seven interrelated barriers that collectively explain why no RPABs product has yet received regulatory approval: modest efficacy restricted to biomarker-selected subgroups, significant toxicity, pharmacokinetic mismatch among components, instability of mixed cell banks, lack of standardized quality control methods, regulatory uncertainty, and commercial deprioritization after acquisition. Critically, we distinguish between scientific failure (Sym013, discontinued after early termination of its Phase I trial due to tolerability concerns and pharmacokinetic mismatches) and strategic discontinuation (Sym001 and Sym015, which showed clinical signals but were deprioritized for commercial reasons). All clinical and manufacturing data analyzed in this review are derived exclusively from Symphogen's proprietary Sympress™ platform, as no other RPABs candidate from independent developers has entered clinical trials. We conclude that without independent validation of manufacturing consistency, pharmacokinetic-based component ratio design, and a dedicated regulatory pathway, RPABs face an uncertain future. Recommendations for future development are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.